Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine

Obstetrics and Gynecology

Volumn 102, Issue 3, 2003, Pages 605-611

  Freeman, Robert ^a   Hill, Simon ^b   Millard, Richard ^b   Slack, Mark ^b   Sutherst, John ^b  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TOLTERODINE; BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; NAUSEA; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; XEROPHTHALMIA; XEROSTOMIA; BLADDER DISEASE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; MICTURITION DISORDER; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PROBABILITY; REFERENCE VALUE; RISK; URINE INCONTINENCE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CONFIDENCE INTERVALS; CRESOLS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; ODDS RATIO; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; PROBABILITY; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY BLADDER DISEASES; URINARY INCONTINENCE; URINATION DISORDERS;

EID: 0141921336     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(03)00623-9     Document Type: Article

References (13)

1. Abrams P., Wein A.J. The overactive bladder: A widespread but treatable condition. 1998;Eric Sparre Medical, Stockholm.
2. Jackson S. The patient with overactive bladder - symptoms and quality of life issues. Urology. 50:(Suppl 6A):1997;18-22.
3. Kelleher C.J., Cardozo L.D., Khullar V., Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 104:1997;1374-1379.
4. Kobelt G., Kirchberger I., Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 83:1999;583-590.
5. Wein A.J., Rovner E.S. The overactive bladder An overview for primary care health providers . Int J Fertil Womens Med. 44:1999;56-66.
6. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., Wein A.J. How widespread are the symptoms of an overactive bladder and how do we manage them? A population-based prevalence study. BJU Int. 87:2001;760-766.
7. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother. 11:2000;13-27.
8. Stahl M.M.S., Eckström B., Sparf A., Mattiasson A., Anders son K.-E. Urodynamic and other effects of tolterodine A novel antimuscarinic drug for the treatment of detrusor overactivity . Neurourol Urodyn. 14:1995;647-655.
9. Chapple C.R. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 55:(Suppl 5A):2000;47-49.
10. Van Kerrebroeck P.E.V.A., Kreder K., Jonas U., Zinner N., Wein A.,. Tolterodine once-daily Superior efficacy and tolerability in the treatment of overactive bladder . Urology. 57:2001;414-421.
11. Coolsaet B.L., Van Duyl W.A., Van Os-Bossagh P., De Bakker H.V. New concepts in relation to urge and detrusor activity. Neurourol Urodyn. 12:1993;463-471.
12. Appell R.A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder A pooled analysis . Urology. 50:(Suppl 6A):1997;90-96.
13. Abrams P., Freeman R., Anderström C., Mattiasson A. Tolterodine, a new antimuscarinic agent As effective but better tolerated than oxybutynin in patients with an overactive bladder . Br J Urol. 81:1998;801-810.